by Jeito Life | 29 Nov Mon | English
Quell Therapeutics is the world leader in developing engineered T-regulatory (Tregs) cell therapies for serious medical conditions driven by the immune system. Jeito continues to build a strong portfolio of companies with groundbreaking therapies in areas of high...
by Jeito Life | 13 Oct Wed | English
Partnership will allow SparingVision to develop novel genomic medicines for the treatment of ocular diseases utilizing Intellia’s proprietary CRISPR/Cas9 technology Jeito Capital selected SparingVision as its first French investment in October 2020, participating in a...
by Jeito Life | 20 Sep Mon | English
Oversubscribed Jeito I becomes the largest European fund dedicatedto the life sciences sector. Jeito Capital is dedicated to working with biotech entrepreneurs to provide financial and expert support in continuity to accelerate patients’ access to groundbreaking...
by Jeito Life | 28 Jul Wed | English
The appointment of Dr. Tordjman was granted by French Ministers, Agnès Pannier-Runacher and Franck Riester Paris, France, 28 July 2021 – Jeito Capital (“Jeito”), a rapidly emerging independent Private Equity firm dedicated to biotech and biopharma, today welcomes the...
by Jeito Life | 15 Jun Tue | English
Jeito Capital selects Alentis Therapeutics as its fifth investment since launching the fund Alentis is focused on the development of breakthrough treatments for fibrotic diseases and associated cancers Paris, France, 15 June 2021 – Jeito Capital (“Jeito”), a rapidly...
by Jeito Life | 27 May Thu | English
Jeito selects Pulmocide as its fourth investment since launching the fund Pulmocide is a clinical-stage biopharma company focused on the development of novel treatments for life-threatening respiratory diseases Paris, France, 27 May 2021 – Jeito Capital (“Jeito”), a...
Recent Comments